Suchergebnisse - "Garassino, M C"

PubPharm (48)

11

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy

enthalten in: ESMO open | 2021

von Ganzinelli, M. | Linardou, H. | Alvisi, M. | +14

12

Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Curigliano, G. | Banerjee, S. | Cervantes, A. | +76

13

Immunometabolic Status of COVID-19 Cancer Patients

enthalten in: Physiological reviews | 2020

von Sica, A. | Colombo, M. | Trama, A. | +3

14

Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus

enthalten in: Annals of oncology | 31 July 2020

von Curigliano, G. | Banerjee, S. | Cervantes, A. | +12

15

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC) : what to add and what to leave out

enthalten in: Cancer treatment reviews | 2019

von Proto, C. | Ferrara, R. | Signorelli, D. | +12

16

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Peters, S. | Dafni, U. | Boyer, M. | +21

17

Osimertinib or platinum–pemetrexed in EGFR T790M : positive lung cancer

enthalten in: The New England journal of medicine | 2017

von Mok, T. | Wu, Y. | Garassino, M. | +14

18

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2017

von Peters, S. | Gettinger, S. | Johnson, M. | +25

19

Value of KRAS as prognostic or predictive marker in NSCLC : results from the TAILOR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Rulli, E. | Marabese, M. | Torri, V. | +14

20

Correction to Lancet Oncol 2015; 16 : 747. EGFR mutations and EGFR tyrosine kinase inhibitors

enthalten in: The Lancet. Oncology | 2015

von Torri, V. | Broggini, M. | Garassino, M.

ErratumFor: Lancet Oncol. 2015 Jul;16(7):746-8. - PMID 26051233